A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease. Studies comparing R-CHOP with modified regimens replacing R with obinutuzumab (O) or addin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherng, Hua-Jay J., Alig, Stefan K., Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva S., Turturro, Francesco, Hagemeister, Fredrick, Craig, Alexander F. M., Macaulay, Charles W., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy J., Flowers, Christopher R., Vega, Francisco, Green, Michael R., Feng, Lei, Kurtz, David M., Alizadeh, Ash A., Davis, R. Eric, Westin, Jason R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111343/
https://www.ncbi.nlm.nih.gov/pubmed/36375046
http://dx.doi.org/10.1182/bloodadvances.2022008174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111343/
https://www.ncbi.nlm.nih.gov/pubmed/36375046
http://dx.doi.org/10.1182/bloodadvances.2022008174

Ejemplares similares